Stock Yards Bank & Trust Co. reduced its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 13.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,672 shares of the company's stock after selling 10,343 shares during the quarter. Stock Yards Bank & Trust Co.'s holdings in AbbVie were worth $11,492,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. RPg Family Wealth Advisory LLC bought a new stake in shares of AbbVie during the third quarter valued at approximately $28,000. Fiduciary Advisors Inc. bought a new position in AbbVie in the fourth quarter valued at approximately $29,000. Retirement Wealth Solutions LLC bought a new position in AbbVie in the fourth quarter valued at approximately $35,000. Marquette Asset Management LLC bought a new position in AbbVie in the third quarter valued at approximately $39,000. Finally, Mizuho Securities Co. Ltd. boosted its stake in AbbVie by 100.0% in the third quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company's stock valued at $39,000 after acquiring an additional 100 shares during the last quarter. 70.23% of the stock is owned by institutional investors.
Insider Buying and Selling at AbbVie
In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.25% of the company's stock.
Analyst Ratings Changes
ABBV has been the topic of a number of recent research reports. Raymond James reaffirmed an "outperform" rating and issued a $220.00 price objective (up from $218.00) on shares of AbbVie in a research note on Monday. Leerink Partners raised shares of AbbVie from a "market perform" rating to an "outperform" rating and set a $206.00 price objective on the stock in a research note on Friday, November 22nd. Leerink Partnrs raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 22nd. Argus raised shares of AbbVie from a "hold" rating to a "buy" rating in a research note on Monday, November 4th. Finally, Morgan Stanley increased their target price on shares of AbbVie from $224.00 to $239.00 and gave the stock an "overweight" rating in a report on Monday. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $208.35.
View Our Latest Research Report on ABBV
AbbVie Stock Down 0.1 %
Shares of NYSE:ABBV traded down $0.17 during midday trading on Tuesday, reaching $189.97. 7,374,021 shares of the company were exchanged, compared to its average volume of 6,435,744. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The stock has a fifty day simple moving average of $176.84 and a two-hundred day simple moving average of $185.26. The firm has a market cap of $335.71 billion, a PE ratio of 79.16, a P/E/G ratio of 1.84 and a beta of 0.58.
AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter last year, the business earned $2.79 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.26 earnings per share for the current year.
AbbVie Profile
(
Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Further Reading
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
